US 12,274,742 B2
MDR E. coli immunogen
Eszter Nagy, Wein (AT); Gábor Nagy, Sopron (HU); Valéria Szijárto, Vienna (AT); Zóltan Magyarics, Vienna (AT); Irina Mirkina, Vienna (AT); Luis Gauchalla, Vienna (AT); Adriana Badarau, Vienna (AT); Gerhild Zauner, Vienna (AT); and Jolanta Lukasiewicz, Wroclaw (PL)
Assigned to Janssen Pharmaceuticals, Inc.
Filed by Janssen Pharmaceuticals, Inc., Titusville, NJ (US)
Filed on Nov. 22, 2022, as Appl. No. 18/057,957.
Application 17/167,595 is a division of application No. 16/229,223, filed on Dec. 21, 2018, granted, now 10,940,191, issued on Mar. 9, 2021.
Application 15/373,528 is a division of application No. 14/651,156, granted, now 9,849,169, issued on Dec. 26, 2017, previously published as PCT/EP2014/050895, filed on Jan. 17, 2014.
Application 18/057,957 is a continuation of application No. 17/167,595, filed on Feb. 4, 2021, granted, now 11,529,405.
Application 16/229,223 is a continuation of application No. 15/373,528, filed on Dec. 9, 2016, granted, now 10,206,992, issued on Feb. 19, 2019.
Claims priority of application No. 13151627 (EP), filed on Jan. 17, 2013.
Prior Publication US 2023/0277643 A1, Sep. 7, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 39/108 (2006.01); A61K 39/00 (2006.01); C07K 16/12 (2006.01); G01N 33/569 (2006.01)
CPC A61K 39/0258 (2013.01) [C07K 16/1232 (2013.01); G01N 33/56916 (2013.01); A61K 2039/505 (2013.01); A61K 2039/55505 (2013.01); A61K 2039/55511 (2013.01); A61K 2039/55561 (2013.01); C07K 2317/33 (2013.01); C07K 2317/73 (2013.01); C07K 2317/92 (2013.01); G01N 2333/245 (2013.01); G01N 2469/10 (2013.01)] 11 Claims
 
1. A vaccine formulation comprising:
(a) an isolated O25b antigen having a repeating unit of the structure of:

OG Complex Work Unit Chemistry
(b) an isolated second antigen not natively associated with the O25b antigen;
wherein the vaccine is formulated for intramuscular injection.